Evidence map›Paper›PMID 42376517›Full record

ReviewOpen veterinary journal2025

Hepatic stellate cells in liver fibrosis: From biology to pathology.

Hicham Esselmani, Youssef Nadir, Rahma Ennadi, Nadia Zouhairi, Omar El Hiba, Mohammed Amine Lkousse, Mustapha Najimi, Mohamed Merzouki

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hicham EsselmaniFaculty of Science and Technology, Biological Engineering Laboratory, Sultan Moulay Slimane University, Beni Mellal, Morocco.
Youssef NadirFaculty of Science and Technology, Biological Engineering Laboratory, Sultan Moulay Slimane University, Beni Mellal, Morocco.
Rahma EnnadiFaculty of Science and Technology, Biological Engineering Laboratory, Sultan Moulay Slimane University, Beni Mellal, Morocco.
Nadia ZouhairiFaculty of Science and Technology, Biological Engineering Laboratory, Sultan Moulay Slimane University, Beni Mellal, Morocco.
Omar El HibaBiotechnologies and Health Laboratory, Neurosciences and Toxicology Team, Faculty of Sciences, Chouaib Doukkali University, El Jadida, Morocco.
Mohammed Amine LkousseFaculty of Medicine and Pharmacy, Sultan Moulay Slimane University, Beni Mellal, Morocco.
Mustapha NajimiLaboratory of Pediatric Hepatology and Cell Therapy, Institute of Experimental and Clinical Research, Brussels, Belgium.
Mohamed MerzoukiFaculty of Science and Technology, Biological Engineering Laboratory, Sultan Moulay Slimane University, Beni Mellal, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic stellate cells (HSCs) are pivotal in the development of liver fibrosis, a serious condition characterized by excessive extracellular matrix (ECM) accumulation and compromised liver function. HSCs remain dormant in a healthy liver, effectively storing vitamin A and ensuring ECM stability. However, when faced with injuries from viral hepatitis, alcohol abuse, or nonalcoholic steatohepatitis, these cells are activated and transform into proliferative, ECM-producing myofibroblasts. This review provides a comprehensive overview of the biology of HSCs and their transition from a quiescent to an activated state. The key signaling pathways (e.g., transforming growth factor-beta, platelet-derived growth factor, Wnt/β-catenin) and cellular interactions that drive hepatocyte stem cell (HSC) activation are examined, with a special emphasis on emerging themes such as metabolic reprogramming and epigenetic control. Furthermore, the landscape of antifibrotic therapies targeting HSCs, from pathway inhibitors and epigenetic drugs to ribonucleic acid based strategies, is critically evaluated, and their translational potential and challenges are discussed. By integrating foundational knowledge with recent advances-including insights from single-cell technologies revealing HSC heterogeneity-this review aims to offer a timely and critical perspective on the pathobiology of HSCs and the evolving strategies to combat liver fibrosis.

Indexed as

Hepatic Stellate CellsLiver CirrhosisAnimalsHumansSignal TransductionExtracellular matrixFibrosis therapeuticsHepatic stellate cellsLiver fibrosis

Identifiers

PMID42376517
PMCPMC13313938

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.